U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07358195) titled 'Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation' on Jan. 05.
Brief Summary: The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Kidney Failure Chronic
Stem Cell Transplant
Stem Cell Transplant Complications
Tolerance
Hematologic Cancer
Intervention:
DRUG: Venetoclax
Venetocla...